Third-party lab testing: 3 independent Janoshik assays on file, most recent test 2026-03-30.
Peptide supplier identified through Janoshik analytical testing records.
Estrapen is listed as active. Discovered via Janoshik third-party lab testing.
| Substance | Measured purity | Test date |
|---|---|---|
| 50mg/mL Estradiol Enanthate | not reported | 2026-03-30 |
| 50mg/mL Estradiol Enanthate | not reported | 2026-03-27 |
| 50mg/mL Estradiol Enanthate | not reported | 2026-03-27 |
None of these 3 assays carry a purity number on the certificate. They confirm the substance was submitted and tested, which is not the same as a measured result and not the same as a failure.
| Status | Active |
|---|---|
| Independent assays on file | 3 |
| Certificates of analysis | Vendor states COAs are available |
| Vendor type | Research-use supplier |
Estrapen is listed as active and we hold 3 independent Janoshik assays on file. That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. We hold 3 third-party Janoshik assays for Estrapen. The most recent is dated 2026-03-30.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Eternal Peptides Review, Ethos Peptide Research Review, Evolution Peptides Review.